About BioMonde
BioMonde is a Healthcare company based in Gainesville (United States) founded in 2014. Larva therapy is manufactured for debridement of non-healing wounds. BioMonde has raised $5.9 million across 1 funding round from investors including Oxford Capital and Development Bank of Wales. BioMonde offers products and services including BioBag and Larval Therapy. Its focus areas include Life Sciences, Cell Therapy, Diversified and Wound Care. Its legal entity is BioMonde Ltd. Its competitors include Tenaya Therapeutics, Orca Bio and Athira Pharma; 3 of its 3 listed competitors have raised funding.
Company details
BioMonde was founded in 2014 and is based in Gainesville, United States, within the medical devices sector. Larva therapy products, including the BioBag device, are produced using an aseptic process involving greenbottle fly larvae. These are supplied for debridement of wounds such as pressure ulcers, diabetic ulcers, venous stasis ulcers, and surgical or traumatic injuries. Operations occur in a specialized manufacturing facility.
- Total Equity Funding$5.9M (USD)
in 1 rounds
- Latest Funding Round$5.9M (USD), Series A
Jun 2014
- InvestorsOxford Capital
& 1 more
Products & Services of BioMonde
BioMonde offers a comprehensive portfolio of products and services, including BioBag and Larval Therapy.
Net dressing containing larvae for effective wound debridement.
Natural treatment for rapid and selective wound bed preparation.
Apps and channels of BioMonde
its YouTube channel BioMonde has 305 subscribers and 30 videos.
Videos from BioMonde
The most watched videos on BioMonde's YouTube channel, BioMonde (305 subscribers). Click a video to play it here.
More on BioMonde.
Funding Insights of BioMonde
BioMonde has successfully raised a total of $5.9M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.9 million completed in June 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.9M
- Total Rounds 1
- Last Round Series A — $5.9M
- First Round $5.9M
(Jun 2014)
- Investors Count 2
All 1 funding rounds of BioMonde with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2014 | $5.9M | Series A | – | Oxford Capital, Finance Wales | – |
2 investors in total: 2 institutional.
Investors in BioMonde
BioMonde has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Oxford Capital and Development Bank of Wales.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage venture capital is invested in UK technology sectors. | oxcp.com | Oxford, United Kingdom | ||
Sustainable business finance is provided for companies in Wales. | financewales.co.uk | Wrexham, United Kingdom |
Investor details for BioMonde
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of BioMonde
2 dated milestones of BioMonde, from founding to its latest funding, stage changes and deals.
- Founded BioMonde is founded.
- Funding First funding round of $5.9M.
Competitors of BioMonde
BioMonde has 3 listed competitors in our database, 3 of them funded. They include Tenaya Therapeutics, Orca Bio and Athira Pharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tenayatherapeutics.com | 2016 | San Francisco, United States | $142M | 140 | Regenerative and gene therapeutics for heart failure are developed. | |
| orcabio.com | 2016 | Menlo Park, United States | $300M | 66 | Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | |
| athira.com | 2011 | Seattle, United States | $121.04M | 62 | Neurodegenerative disease therapeutics, including for Alzheimer’s and Parkinson’s, are developed. |
Detailed competitors of BioMonde
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BioMonde
The website of BioMonde (biomonde.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▼ 20.5% vs previous month
Top companies in Cell Therapy
3 companies that operate in the same segment as BioMonde (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biomonde
Complete news archive for BioMonde
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioMonde
BioMonde was founded in 2014.
BioMonde is headquartered in Gainesville, United States.
BioMonde is a funded company, having raised a total of $5.9M across 1 funding round to date. The company's 1st funding round was a Series A of $5.9M, raised on Jun 2014.
BioMonde was founded in 2014 and is based in Gainesville, United States, within the medical devices sector. Larva therapy products, including the BioBag device, are produced using an aseptic process involving greenbottle fly larvae. These are supplied for debridement of wounds such as pressure ulcers, diabetic ulcers, venous stasis ulcers, and surgical or traumatic injuries. Operations occur in a specialized manufacturing facility.
BioMonde's top competitors include Tenaya Therapeutics, Athira Pharma and Orca Bio.
BioMonde offers BioBag and Larval Therapy.
BioMonde has 2 investors. Key investors include Oxford Capital, and Development Bank of Wales.
BioMonde operates through Biomonde Ltd..